Aardvark Therapeutics, Inc. Common Stock AARD Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$21.59M-22.7% | -$17.6M-7.9% | -$16.32M-13.6% | -$14.37M-54.3% | -$9.31M-6.0% | ||
| $11K+10.0% | $10K0.0% | $10K-9.1% | $11K+120% | $5K-37.5% | ||
| $2M+26.8% | $1.58M+5.4% | $1.5M+137% | $634K+172% | $233K+34.7% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $2.42M— | —— | —— | $2.58M+297% | $648K-45.7% | ||
| -$1.26M-158% | $2.17M+112% | $1.03M-43.2% | $1.81M+28.2% | $1.41M— | ||
| $333K-9.8% | $369K-71.9% | $1.31M— | $0-100% | $4.36M+1,425% | ||
| -$13K+31.6% | -$19K-153% | $36K+614% | -$7K+53.3% | -$15K+67.4% | ||
| -$105K-1.0% | -$104K-4.0% | -$100K-23.5% | -$81K-52.8% | -$53K+40.4% | ||
| -$18.87M-12.2% | -$16.81M-4.2% | -$16.13M-63.9% | -$9.84M+13.6% | -$11.39M-47.4% | ||
| —— | $0-100% | $4K-95.6% | $91K— | $0-100% | ||
| $0-100% | $4.95M— | —— | —— | $124.65M+948% | ||
| $34.25M+17.1% | $29.25M0.0% | $29.25M+208% | $9.5M-21.0% | $12.03M— | ||
| $34.25M— | —— | —— | —— | -$112.62M-847% | ||
| $4K— | —— | $171K+2,750% | $6K-94.5% | $110K+165% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $4K-98.5% | $274K+60.2% | $171K— | $0-100% | $88.88M— | ||
| $15.39M— | —— | —— | -$506K+98.6% | -$35.14M— | ||
| $118K-49.4% | $233K-37.4% | $372K-40.0% | $620K+665% | $81K-15.6% | ||
| -$105K-1.0% | -$104K-4.0% | -$100K-23.5% | -$81K-52.8% | -$53K+40.4% | ||
| $333K-9.8% | $369K-71.9% | $1.31M— | $0-100% | $4.36M+1,425% | ||
| $86K+2.4% | $84K+1.2% | $83K-21.7% | $106K-0.9% | $107K+0.9% | ||
| $0-100% | $4.95M— | —— | —— | $124.65M+948% | ||
| $34.25M+17.1% | $29.25M0.0% | $29.25M+208% | $9.5M-21.0% | $12.03M— | ||
| $0— | —— | —— | $77K-96.7% | $2.31M+14,538% | ||
| $0— | —— | —— | —— | $91.08M— | ||
| -$105K-1.0% | -$104K-4.0% | -$100K-23.5% | -$81K-52.8% | -$53K+40.4% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| -$13K+31.6% | -$19K-153% | $36K+614% | -$7K+53.3% | -$15K+67.4% | ||
| $0— | —— | —— | —— | $126.76M— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| —— | $6.5K0.0% | $6.5K0.0% | $6.5K0.0% | $6.5K+225% | ||
| —— | -$16.81M-4.2% | -$16.13M-62.4% | -$9.94M+12.8% | -$11.39M-47.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Aardvark Therapeutics, Inc. Common Stock generate?
- Aardvark Therapeutics, Inc. Common Stock (AARD) generated -$61.7M in operating cash flow over the trailing twelve months.
- Where does Aardvark Therapeutics, Inc. Common Stock's cash flow data come from?
- Every line is extracted from Aardvark Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.